Edwards Lifesciences Corp (EW) · Nov 4, 2026 · Earnings

Edwards earnings beat and raise, led by TMTT growth

Beat — Adjusted EPS $0.80 vs ~$0.74 consensus

Edwards Lifesciences earnings beat consensus as TMTT surged 44%, prompting higher 2026 sales, TAVR and TMTT guidance.

Edwards is in the middle of shifting from a TAVR-led franchise toward a broader structural-heart portfolio, with mitral and tricuspid therapies becoming the faster-growing engine. Its prior Q2 update had already raised 2026 sales, TAVR and TMTT guidance, while keeping adjusted EPS at $2.95–$3.05.

The quarter cleared both the operating and earnings bar. Sales reached $1.716 billion versus a published consensus of about $1.68 billion, while adjusted EPS was $0.80 versus roughly $0.74 expected. The filing attributes the EPS upside to better top-line performance and planned phasing of R&D and SG&A spending.

MetricQ3 2026Q3 2025Consensus / prior guide
Net sales (Financial Statements)$1,715.5M$1,553.1M~$1,680M consensus
Adjusted EPS (Non-GAAP reconciliation)$0.80$0.67~$0.74 consensus
TAVR growth (Outlook)9%–9.5%—8%–9% prior guide
TMTT sales (Outlook)$780M–$790M—$760M–$780M prior guide
Adjusted EPS (Outlook)$2.97–$3.05—$2.95–$3.05 prior guide

The important business signal is the breadth of growth, not just the beat. TAVR grew 8.8% on a constant-currency basis, but TMTT grew 45.6%, with new PASCAL and EVOQUE approvals expanding the addressable mitral and tricuspid opportunity. The core TAVR franchise is also holding together: U.S. competitive position was stable sequentially and modestly higher year over year, while the updated CMS coverage policy and new Japanese reimbursement support access.

Management raised the full-year bar, but the quality of the raise is partly mix-driven. Total 2026 sales-growth guidance moved to approximately 11.5% from 10%–11%, TAVR growth rose to 9%–9.5% from 8%–9%, and TMTT guidance increased to $780M–$790M. 〔0〕 The company now expects future growth to rely more on procedure volumes and less on share gains, which makes the outlook healthier if those volume trends persist but less dependent on continued competitive wins.

The headline earnings strength should be read through the large special charges. GAAP operating income was pressured by a $220.2 million impairment charge tied to acquired in-process R&D and fixed assets, leaving GAAP diluted EPS at $0.53 versus adjusted EPS of $0.80. That charge does not negate the operating beat, but it shows that parts of the acquisition and investment portfolio are still being reset.

Bottom line: This was a genuinely better-than-expected quarter with a meaningful guidance lift, led by accelerating TMTT growth and improving procedure demand. The event strengthens Edwards’ broadening structural-heart story, although the GAAP impairment highlights lingering costs from past investments.

What to watch next

Q4 results and 2027 outlook

Original filing on SEC EDGAR

More Edwards Lifesciences Corp news

Edwards earnings beat and raise, led by TMTT growth | EW Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.